You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

ORVATEN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Orvaten patents expire, and when can generic versions of Orvaten launch?

Orvaten is a drug marketed by Upsher Smith Labs and is included in one NDA.

The generic ingredient in ORVATEN is midodrine hydrochloride. There are thirteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the midodrine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Orvaten

A generic version of ORVATEN was approved as midodrine hydrochloride by MYLAN PHARMS INC on September 10th, 2003.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ORVATEN?
  • What are the global sales for ORVATEN?
  • What is Average Wholesale Price for ORVATEN?
Drug patent expirations by year for ORVATEN
Recent Clinical Trials for ORVATEN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
James J. Peters Veterans Affairs Medical CenterPhase 4
The Craig H. Neilsen FoundationPhase 4

See all ORVATEN clinical trials

Pharmacology for ORVATEN

US Patents and Regulatory Information for ORVATEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher Smith Labs ORVATEN midodrine hydrochloride TABLET;ORAL 076725-001 Nov 3, 2004 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Upsher Smith Labs ORVATEN midodrine hydrochloride TABLET;ORAL 076725-002 Nov 3, 2004 AB RX No Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Upsher Smith Labs ORVATEN midodrine hydrochloride TABLET;ORAL 076725-003 Nov 3, 2004 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.